Turning off cancer’s growth switches. Interview with Steven Yatomi-Clarke, CEO of Prescient Therapeutics, on targeted medicine
Cancer has been on the public radar for many years now and, although several drugs...
Cancer has been on the public radar for many years now and, although several drugs...
We maintain our Buy rating and are increasing our price target to A$0.20 from A$0.16...
Whether a day trader or a long-term investor, we often examine research released by industry...
We maintain our Buy rating and are increasing our price target to A$0.16from A$0.09. The...
Prescient Therapeutics (PTX) shares rose 60 per cent this morning after expanding its Phase 1b...
Cancer drug developer Prescient Therapeutics (ASX: PTX) is expanding its Phase 1b study in patients with acute...
This week we were joined in office by Prescient Therapeutics (ASX: PTX) CEO and Managing...
Humankind has been trying to find a cure for cancer for thousands of years. Today,...
Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company which is engaged in small molecule drug...
Oncology company Prescient Therapeutics (ASX: PTX) has unveiled a potentially lucrative collaboration with Adelaide-based Carina Biotech to...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.